627 related articles for article (PubMed ID: 25003359)
41. Randomized, open-label study to evaluate patient-reported outcomes with fingolimod after changing from prior disease-modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design.
Cascione M; Wynn D; Barbato LM; Pestreich L; Schofield L; McCague K
J Med Econ; 2013 Jul; 16(7):859-65. PubMed ID: 23647445
[TBL] [Abstract][Full Text] [Related]
42. The spot sign and tranexamic acid on preventing ICH growth--AUStralasia Trial (STOP-AUST): protocol of a phase II randomized, placebo-controlled, double-blind, multicenter trial.
Meretoja A; Churilov L; Campbell BC; Aviv RI; Yassi N; Barras C; Mitchell P; Yan B; Nandurkar H; Bladin C; Wijeratne T; Spratt NJ; Jannes J; Sturm J; Rupasinghe J; Zavala J; Lee A; Kleinig T; Markus R; Delcourt C; Mahant N; Parsons MW; Levi C; Anderson CS; Donnan GA; Davis SM
Int J Stroke; 2014 Jun; 9(4):519-24. PubMed ID: 23981692
[TBL] [Abstract][Full Text] [Related]
43. T-cell response against varicella-zoster virus in fingolimod-treated MS patients.
Ricklin ME; Lorscheider J; Waschbisch A; Paroz C; Mehta SK; Pierson DL; Kuhle J; Fischer-Barnicol B; Sprenger T; Lindberg RL; Kappos L; Derfuss T
Neurology; 2013 Jul; 81(2):174-81. PubMed ID: 23700335
[TBL] [Abstract][Full Text] [Related]
44. Early Clinical and Radiological Course, Management, and Outcome of Intracerebral Hemorrhage Related to New Oral Anticoagulants.
Purrucker JC; Haas K; Rizos T; Khan S; Wolf M; Hennerici MG; Poli S; Kleinschnitz C; Steiner T; Heuschmann PU; Veltkamp R
JAMA Neurol; 2016 Feb; 73(2):169-77. PubMed ID: 26660118
[TBL] [Abstract][Full Text] [Related]
45. Decompressive hemicraniectomy without clot evacuation in dominant-sided intracerebral hemorrhage with ICP crisis.
Heuts SG; Bruce SS; Zacharia BE; Hickman ZL; Kellner CP; Sussman ES; McDowell MM; Bruce RA; Connolly ES
Neurosurg Focus; 2013 May; 34(5):E4. PubMed ID: 23634923
[TBL] [Abstract][Full Text] [Related]
46. Fingolimod: a novel immunosuppressant for multiple sclerosis.
Brown BA; Kantesaria PP; McDevitt LM
Ann Pharmacother; 2007 Oct; 41(10):1660-8. PubMed ID: 17785617
[TBL] [Abstract][Full Text] [Related]
47. Cost-effectiveness of early initiation of fingolimod versus delayed initiation after 1 year of intramuscular interferon beta-1a in patients with multiple sclerosis.
Agashivala N; Kim E
Clin Ther; 2012 Jul; 34(7):1583-90. PubMed ID: 22749258
[TBL] [Abstract][Full Text] [Related]
48. Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment.
Havla JB; Pellkofer HL; Meinl I; Gerdes LA; Hohlfeld R; Kümpfel T
Arch Neurol; 2012 Feb; 69(2):262-4. PubMed ID: 22332194
[TBL] [Abstract][Full Text] [Related]
49. Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report.
Leypoldt F; Münchau A; Moeller F; Bester M; Gerloff C; Heesen C
Neurology; 2009 Mar; 72(11):1022-4. PubMed ID: 19289744
[No Abstract] [Full Text] [Related]
50. Perihematomal Edema Expansion Rates and Patient Outcomes in Deep and Lobar Intracerebral Hemorrhage.
Grunwald Z; Beslow LA; Urday S; Vashkevich A; Ayres A; Greenberg SM; Goldstein JN; Leasure A; Shi FD; Kahle KT; Battey TW; Simard JM; Rosand J; Kimberly WT; Sheth KN
Neurocrit Care; 2017 Apr; 26(2):205-212. PubMed ID: 27844466
[TBL] [Abstract][Full Text] [Related]
51. Perfusion-weighted magnetic resonance imaging in acute intracerebral hemorrhage at baseline and during the 1st and 2nd week: a longitudinal study.
Pascual AM; López-Mut JV; Benlloch V; Chamarro R; Soler J; Láinez MJ
Cerebrovasc Dis; 2007; 23(1):6-13. PubMed ID: 16968980
[TBL] [Abstract][Full Text] [Related]
52. Population pharmacokinetics of fingolimod phosphate in healthy participants.
Wu K; Mercier F; David OJ; Schmouder RL; Looby M
J Clin Pharmacol; 2012 Jul; 52(7):1054-68. PubMed ID: 22110161
[TBL] [Abstract][Full Text] [Related]
53. Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis.
Bergvall N; Makin C; Lahoz R; Agashivala N; Pradhan A; Capkun G; Petrilla A; Karkare SU; Balderston McGuiness C; Korn JR
Curr Med Res Opin; 2013 Dec; 29(12):1647-56. PubMed ID: 24059944
[TBL] [Abstract][Full Text] [Related]
54. Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose fingolimod (FTY720) in adolescents with stable renal transplants.
Ettenger R; Schmouder R; Kovarik JM; Bastien MC; Hoyer PF
Pediatr Transplant; 2011 Jun; 15(4):406-13. PubMed ID: 21585629
[TBL] [Abstract][Full Text] [Related]
55. Perihematomal Edema and Functional Outcomes in Intracerebral Hemorrhage: Influence of Hematoma Volume and Location.
Murthy SB; Moradiya Y; Dawson J; Lees KR; Hanley DF; Ziai WC;
Stroke; 2015 Nov; 46(11):3088-92. PubMed ID: 26396030
[TBL] [Abstract][Full Text] [Related]
56. Rationale and Design of a Randomized, Double-Blind Trial Evaluating the Efficacy of Tranexamic Acid on Hematoma Expansion and Peri-hematomal Edema in Patients with Spontaneous Intracerebral Hemorrhage within 4.5 h after Symptom Onset: The THE-ICH Trial Protocol.
Jiang C; Wang J; Wang J; Zhang J;
J Stroke Cerebrovasc Dis; 2020 Oct; 29(10):105136. PubMed ID: 32912508
[TBL] [Abstract][Full Text] [Related]
57. FTY720 is neuroprotective and improves functional outcomes after intracerebral hemorrhage in mice.
Rolland WB; Manaenko A; Lekic T; Hasegawa Y; Ostrowski R; Tang J; Zhang JH
Acta Neurochir Suppl; 2011; 111():213-7. PubMed ID: 21725758
[TBL] [Abstract][Full Text] [Related]
58. Prognostic significance of perihematomal edema in acute intracerebral hemorrhage: pooled analysis from the intensive blood pressure reduction in acute cerebral hemorrhage trial studies.
Yang J; Arima H; Wu G; Heeley E; Delcourt C; Zhou J; Chen G; Wang X; Zhang S; Yu S; Chalmers J; Anderson CS;
Stroke; 2015 Apr; 46(4):1009-13. PubMed ID: 25712944
[TBL] [Abstract][Full Text] [Related]
59. Absorption and disposition of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in healthy volunteers: a case of xenobiotic biotransformation following endogenous metabolic pathways.
Zollinger M; Gschwind HP; Jin Y; Sayer C; Zécri F; Hartmann S
Drug Metab Dispos; 2011 Feb; 39(2):199-207. PubMed ID: 21045200
[TBL] [Abstract][Full Text] [Related]
60. Fingolimod-associated macular edema: incidence, detection, and management.
Jain N; Bhatti MT
Neurology; 2012 Feb; 78(9):672-80. PubMed ID: 22371414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
